CV Ingenuity is a Palo Alto, CA-based medical device company focused on developing a drug-eluting balloon platform to treat peripheral artery disease and reduce restenosis. The company's core product is a drug-eluting balloon technology intended to address PAD and prevent restenosis following interventions. CV Ingenuity is led by CEO Duke Rohlen. The company closed a $16m Series B financing led by New Enterprise Associates, with participation from existing investors BioStar Ventures, Synergy Ventures and Western Technology. It intends to use the funds to accelerate product development and expand its executive team. As part of the financing, NEA General Partner Ryan Drant and principal Justin Klein will join the company's board of directors.

Total raised

$16M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2011